English

Valion Bio, Inc.

EDGAR

TIVC Current report (8-K) · filed 2026-10-29

Annual consolidated revenue for 2024: about USD 780K, using the latest reported figures. The previous period, 2023, was about USD 1.176M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

146 thousand USD

2025 Q3 · USD

Exact inputs and evidence

Revenue: 146000 USD Source

Operating margin

-1,700.68%

2025 Q3 · %

Exact inputs and evidence

Operating Income: -2483000 USD Source
Revenue: 146000 USD Source

Operating cash flow

-1.98 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -4700000 USD Source
Operating Cash Flow: -2716000 USD Source

Free cash flow

-1.99 million USD

2025 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: -4700000 USD Source
Operating Cash Flow: -2716000 USD Source
Capital Expenditure: 13000 USD Source
Capital Expenditure: 3000 USD Source

Cash and cash equivalents: 2.1 million USD 2026-06-30 Source
Exact value

2100000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 4.15 million shares 2026-06-30 Source
Exact value

4151919 shares

Reported share-count change

329.85% · 3.19 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

965899 shares · 2025-06-30· Source
4151919 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

482 thousand USD

2024-10-01 – 2025-09-30

Exact inputs and evidence

Revenue: 780000 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 600000 USD · 2024-01-01 – 2024-09-30 Source
Revenue: 70000 USD · 2025-01-01 – 2025-03-31 Source
Revenue: 86000 USD · 2025-04-01 – 2025-06-30 Source
Revenue: 146000 USD · 2025-07-01 – 2025-09-30 Source

Net income

-18.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -2596000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -8878000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -6029000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -6202000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -7103000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-14.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -4700000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2716000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -4700000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -10300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -5000000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

99 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 13000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 38000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 13000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 7000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-14.7 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -4700000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2716000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -7000000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -4700000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -5000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -10300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -5000000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 13000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 3000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 38000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 13000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 7000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 64000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 7000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-29.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2024-12-31
Operating income: 5 of 11 periods available· newest 2024-12-31
Net income: 5 of 11 periods available· newest 2024-12-31
Operating cash flow: 5 of 11 periods available· newest 2024-12-31
Capital expenditure: 3 of 11 periods available· newest 2024-12-31
Total assets: 5 of 11 periods available· newest 2024-12-31
Total liabilities: 5 of 11 periods available· newest 2024-12-31
Current assets: 5 of 11 periods available· newest 2024-12-31
Current liabilities: 5 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 5 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-33.7%

Prior period

USD 1.18 million

2023-01-01 – 2023-12-31
Current period

USD 780,000

2024-01-01 – 2024-12-31

Exact inputs and evidence

780000 − 1176000 = -396000 USD

1176000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
780000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Year-over-year change in Revenue: -396000 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 780000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2512888 Filing: 000095017025043234 Input fundies:Revenue: 1176000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2514413 Filing: 000095017025043234
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2.59 million

Prior period

−USD 8.24 million

2023-01-01 – 2023-12-31
Current period

−USD 5.66 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-5655000 − -8244000 = 2589000 USD

-8244000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-5655000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Year-over-year change in Net income: 2589000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -5655000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#2993714 Filing: 000143774926010343 Input fundies:NetIncome: -8244000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#3444081 Filing: 000095017025043234
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 2.81 million

Prior period

−USD 8.51 million

2023-01-01 – 2023-12-31
Current period

−USD 5.7 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-5700000 − -8511000 = 2811000 USD

-8511000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-5700000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Year-over-year change in Operating cash flow: 2811000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -5700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#2026002 Filing: 000143774926010343 Input fundies:OperatingCashFlow: -8511000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2379147 Filing: 000095017025043234
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 118,000

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

-0 − 118000 = -118000 USD

118000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Year-over-year change in Capital expenditure: -118000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: -0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#1976559 Filing: 000143774926010343 Input fundies:CapitalExpenditure: 118000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2385033 Filing: 000095017025043234
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 780,000 100% of revenue
Cost of revenue USD 778,000 100% of revenue
Operating expenses USD 4.48 million 574% of revenue
Operating income −USD 4.48 million −574% of revenue
Tax, interest and other Derived USD 1.18 million 151% of revenue
Net income −USD 5.66 million −725% of revenue

Cash

Operating cash flow −USD 5.7 million −731% of revenue
Capital expenditure USD 0 −0% of revenue
Free cash flow Derived −USD 5.7 million −731% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 473% of revenue.
2021 Operating loss: operating costs were 548% of revenue.
2022 Operating loss: operating costs were 649% of revenue.
2023 Operating loss: operating costs were 801% of revenue.
2024 Operating loss: operating costs were 674% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	860000	4064000 Derived	-3204000	435000 Derived	-3639000	Unavailable	Source 2020-01-01 – 2020-12-31: 860000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -3204000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -3639000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -3027000 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	1257000	6890000 Derived	-5633000	2861000 Derived	-8494000	Unavailable	Source 2021-01-01 – 2021-12-31: 1257000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -5633000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -8494000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -5612000 USD Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	1840000	11938000 Derived	-10098000	-2000 Derived	-10096000	-8930000 Derived	Source 2022-01-01 – 2022-12-31: 1840000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -10098000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -10096000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -8919000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 11000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	1176000	9421000 Derived	-8245000	-1000 Derived	-8244000	-8629000 Derived	Source 2023-01-01 – 2023-12-31: 1176000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -8245000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -8244000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -8511000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 118000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	780000	5256000 Derived	-4476000	1179000 Derived	-5655000	-5700000 Derived	Source 2024-01-01 – 2024-12-31: 780000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -4476000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -5655000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -5700000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: -0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 780K 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	860000	Revenue: 860000 Open source
20212021-12-31	Revenue	1257000	Revenue: 1257000 Open source
20222022-12-31	Revenue	1840000	Revenue: 1840000 Open source
20232023-12-31	Revenue	1176000	Revenue: 1176000 Open source
20242024-12-31	Revenue	780000	Revenue: 780000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-33.7% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 860000 Open source
20212021-12-31	Year over year	46.2%	Revenue: 1257000 Open source Revenue: 860000 Open source
20222022-12-31	Year over year	46.4%	Revenue: 1840000 Open source Revenue: 1257000 Open source
20232023-12-31	Year over year	-36.1%	Revenue: 1176000 Open source Revenue: 1840000 Open source
20242024-12-31	Year over year	-33.7%	Revenue: 780000 Open source Revenue: 1176000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -573.8% 2024

Net margin -725% 2024

Free cash flow margin -730.8% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-372.6%	Operating Income: -3204000 Open source Revenue: 860000 Open source
20212021-12-31	Operating margin	-448.1%	Operating Income: -5633000 Open source Revenue: 1257000 Open source
20222022-12-31	Operating margin	-548.8%	Operating Income: -10098000 Open source Revenue: 1840000 Open source
20232023-12-31	Operating margin	-701.1%	Operating Income: -8245000 Open source Revenue: 1176000 Open source
20242024-12-31	Operating margin	-573.8%	Operating Income: -4476000 Open source Revenue: 780000 Open source
20202020-12-31	Net margin	-423.1%	Net Income: -3639000 Open source Revenue: 860000 Open source
20212021-12-31	Net margin	-675.7%	Net Income: -8494000 Open source Revenue: 1257000 Open source
20222022-12-31	Net margin	-548.7%	Net Income: -10096000 Open source Revenue: 1840000 Open source
20232023-12-31	Net margin	-701%	Net Income: -8244000 Open source Revenue: 1176000 Open source
20242024-12-31	Net margin	-725%	Net Income: -5655000 Open source Revenue: 780000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 860000 Open source Operating Cash Flow: -3027000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 1257000 Open source Operating Cash Flow: -5612000 Open source
20222022-12-31	Free cash flow margin	-485.3%	Revenue: 1840000 Open source Operating Cash Flow: -8919000 Open source Capital Expenditure: 11000 Open source
20232023-12-31	Free cash flow margin	-733.8%	Revenue: 1176000 Open source Operating Cash Flow: -8511000 Open source Capital Expenditure: 118000 Open source
20242024-12-31	Free cash flow margin	-730.8%	Revenue: 780000 Open source Operating Cash Flow: -5700000 Open source Capital Expenditure: -0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -5.7M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	-3027000	Operating Cash Flow: -3027000 Open source
20212021-12-31	Operating cash flow	-5612000	Operating Cash Flow: -5612000 Open source
20222022-12-31	Operating cash flow	-8919000	Operating Cash Flow: -8919000 Open source
20232023-12-31	Operating cash flow	-8511000	Operating Cash Flow: -8511000 Open source
20242024-12-31	Operating cash flow	-5700000	Operating Cash Flow: -5700000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -5.7M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -3027000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -5612000 Open source
20222022-12-31	Free cash flow	-8930000	Operating Cash Flow: -8919000 Open source Capital Expenditure: 11000 Open source
20232023-12-31	Free cash flow	-8629000	Operating Cash Flow: -8511000 Open source Capital Expenditure: 118000 Open source
20242024-12-31	Free cash flow	-5700000	Operating Cash Flow: -5700000 Open source Capital Expenditure: -0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

9.7% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	176.9%	Total Liabilities: 2708000 Open source Total Assets: 1531000 Open source
20212021-12-31	Liabilities / assets	11.7%	Total Liabilities: 1764000 Open source Total Assets: 15036000 Open source
20222022-12-31	Liabilities / assets	38.2%	Total Liabilities: 2245000 Open source Total Assets: 5875000 Open source
20232023-12-31	Liabilities / assets	30.6%	Total Liabilities: 1577000 Open source Total Assets: 5157000 Open source
20242024-12-31	Liabilities / assets	9.7%	Total Liabilities: 272000 Open source Total Assets: 2807000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

9.7× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	1.17×	Current Assets: 1497000 Open source Current Liabilities: 1275000 Open source
20212021-12-31	Current assets / current liabilities	11.72×	Current Assets: 14289000 Open source Current Liabilities: 1219000 Open source
20222022-12-31	Current assets / current liabilities	2.83×	Current Assets: 5306000 Open source Current Liabilities: 1878000 Open source
20232023-12-31	Current assets / current liabilities	3.32×	Current Assets: 4652000 Open source Current Liabilities: 1401000 Open source
20242024-12-31	Current assets / current liabilities	9.7×	Current Assets: 2639000 Open source Current Liabilities: 272000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	−USD 3.64 million Exact value Exact value: -3639000 USD 2020-01-01 – 2020-12-31: -3639000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Valion Bio, Inc. · 2020-12-31 Valion Bio, Inc. (edgar:1787740) Net Income: -3639000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3639000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312522268956/d428933ds1.htm#2426451 Filing: 000119312522268956 The citation records this snapshot. The page link may show a newer release later.	−USD 3.03 million Exact value Exact value: -3027000 USD 2020-01-01 – 2020-12-31: -3027000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Valion Bio, Inc. · 2020-12-31 Valion Bio, Inc. (edgar:1787740) Operating Cash Flow: -3027000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3027000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312522268956/d428933ds1.htm#1866587 Filing: 000119312522268956 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 8.49 million Exact value Exact value: -8494000 USD 2021-01-01 – 2021-12-31: -8494000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Valion Bio, Inc. · 2021-12-31 Valion Bio, Inc. (edgar:1787740) Net Income: -8494000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8494000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017023011359/tivc-20221231.htm#3692461 Filing: 000095017023011359 The citation records this snapshot. The page link may show a newer release later.	−USD 5.61 million Exact value Exact value: -5612000 USD 2021-01-01 – 2021-12-31: -5612000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Valion Bio, Inc. · 2021-12-31 Valion Bio, Inc. (edgar:1787740) Operating Cash Flow: -5612000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5612000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017023011359/tivc-20221231.htm#2440381 Filing: 000095017023011359 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	−USD 10.1 million Exact value Exact value: -10096000 USD 2022-01-01 – 2022-12-31: -10096000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Valion Bio, Inc. · 2022-12-31 Valion Bio, Inc. (edgar:1787740) Net Income: -10096000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10096000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312524082079/d803187ds1.htm#1769336 Filing: 000119312524082079 The citation records this snapshot. The page link may show a newer release later.	−USD 8.92 million Exact value Exact value: -8919000 USD 2022-01-01 – 2022-12-31: -8919000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Valion Bio, Inc. · 2022-12-31 Valion Bio, Inc. (edgar:1787740) Operating Cash Flow: -8919000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8919000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312524082079/d803187ds1.htm#1218890 Filing: 000119312524082079 The citation records this snapshot. The page link may show a newer release later.	USD 11,000 Exact value Exact value: 11000 USD 2022-01-01 – 2022-12-31: 11000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Valion Bio, Inc. · 2022-12-31 Valion Bio, Inc. (edgar:1787740) Capital Expenditure: 11000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312524082079/d803187ds1.htm#1222641 Filing: 000119312524082079 The citation records this snapshot. The page link may show a newer release later.	−USD 8.93 million Calculation and evidence -8919000 − 11000 USD Exact free cash flow: -8930000 USD 2022-01-01 – 2022-12-31: -8919000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 11000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Valion Bio, Inc. · 2022-12-31 Valion Bio, Inc. (edgar:1787740) Free cash flow: -8930000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8919000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312524082079/d803187ds1.htm#1218890 Filing: 000119312524082079 Input fundies:CapitalExpenditure: 11000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000119312524082079/d803187ds1.htm#1222641 Filing: 000119312524082079 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 8.24 million Exact value Exact value: -8244000 USD 2023-01-01 – 2023-12-31: -8244000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Valion Bio, Inc. · 2023-12-31 Valion Bio, Inc. (edgar:1787740) Net Income: -8244000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8244000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#3444081 Filing: 000095017025043234 The citation records this snapshot. The page link may show a newer release later.	−USD 8.51 million Exact value Exact value: -8511000 USD 2023-01-01 – 2023-12-31: -8511000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Valion Bio, Inc. · 2023-12-31 Valion Bio, Inc. (edgar:1787740) Operating Cash Flow: -8511000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8511000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2379147 Filing: 000095017025043234 The citation records this snapshot. The page link may show a newer release later.	USD 118,000 Exact value Exact value: 118000 USD 2023-01-01 – 2023-12-31: 118000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Valion Bio, Inc. · 2023-12-31 Valion Bio, Inc. (edgar:1787740) Capital Expenditure: 118000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 118000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2385033 Filing: 000095017025043234 The citation records this snapshot. The page link may show a newer release later.	−USD 8.63 million Calculation and evidence -8511000 − 118000 USD Exact free cash flow: -8629000 USD 2023-01-01 – 2023-12-31: -8511000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 118000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Valion Bio, Inc. · 2023-12-31 Valion Bio, Inc. (edgar:1787740) Free cash flow: -8629000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8511000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2379147 Filing: 000095017025043234 Input fundies:CapitalExpenditure: 118000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000095017025043234/tivc-20241231.htm#2385033 Filing: 000095017025043234 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 5.66 million Exact value Exact value: -5655000 USD 2024-01-01 – 2024-12-31: -5655000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Net Income: -5655000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5655000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#2993714 Filing: 000143774926010343 The citation records this snapshot. The page link may show a newer release later.	−USD 5.7 million Exact value Exact value: -5700000 USD 2024-01-01 – 2024-12-31: -5700000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Operating Cash Flow: -5700000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#2026002 Filing: 000143774926010343 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: -0 USD 2024-01-01 – 2024-12-31: -0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Capital Expenditure: -0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: -0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#1976559 Filing: 000143774926010343 The citation records this snapshot. The page link may show a newer release later.	−USD 5.7 million Calculation and evidence -5700000 − -0 USD Exact free cash flow: -5700000 USD 2024-01-01 – 2024-12-31: -5700000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: -0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Valion Bio, Inc. · 2024-12-31 Valion Bio, Inc. (edgar:1787740) Free cash flow: -5700000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:19:19Z Snapshot: 3e30444a4216581077c44f423ce8be06ef2be4055b160acf7d3e4d2760732832 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1787740?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5700000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#2026002 Filing: 000143774926010343 Input fundies:CapitalExpenditure: -0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1787740/000143774926010343/tivc20251231_10k.htm#1976559 Filing: 000143774926010343 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

43 filings · 1,672 latest values · 1,672 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001787740, 1787740, TIVC, VBIO, edgar:1787740

Also known as TIVIC HEALTH SYSTEMS, INC., Tivic Health Systems, Inc., Tivic Health Systems, Inc., Valion Bio, Inc.

Valion Bio, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation